This is a community-generated profile. If you would like to claim it, please .
Prokidney company logo
Cell therapy to treat chronic kidney disease51-200 Employees

Prokidney careers

Cell therapy to treat chronic kidney disease
ProKidney offers treatment of chronic kidney disease (CKD) through innovations in cellular therapy. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.
2 weeks ago
1 month ago
Valuation

$0

Funded over

1 round

Latest round

Seed (Jun 2024)